Role of LncRNA H19 in tumor progression and treatment

IF 2.3 3区生物学 Q3 BIOCHEMICAL RESEARCH METHODS

Molecular and Cellular Probes Pub Date : 2024-04-08 DOI:10.1016/j.mcp.2024.101961

Linjing Li , Yuting Gao , Boyi Yu , Jiahao Zhang , Guorong Ma , Xiaodong Jin

{"title":"Role of LncRNA H19 in tumor progression and treatment","authors":"Linjing Li , Yuting Gao , Boyi Yu , Jiahao Zhang , Guorong Ma , Xiaodong Jin","doi":"10.1016/j.mcp.2024.101961","DOIUrl":null,"url":null,"abstract":"<div><p>As one of the earliest discovered lncRNA molecules, lncRNA H19 is usually expressed in large quantities during embryonic development and is involved in cell differentiation and tissue formation. In recent years, the role of lncRNA H19 in tumors has been gradually recognized. Increasing evidence suggests that its aberrant expression is closely related to cancer development. LncRNA H19 as an oncogene not only promotes the growth, proliferation, invasion and metastasis of many tumors, but also develops resistance to treatment, affecting patients' prognosis and survival. Therefore, in this review, we summarise the extensive research on the involvement of lncRNA H19 in tumor progression and discuss how lncRNA H19, as a key target gene, affects tumor sensitivity to radiotherapy, chemotherapy and immunotherapy by participating in multiple cellular processes and regulating multiple signaling pathways, which provides a promising prospect for further research into the treatment of cancer.</p></div>","PeriodicalId":49799,"journal":{"name":"Molecular and Cellular Probes","volume":"75 ","pages":"Article 101961"},"PeriodicalIF":2.3000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0890850824000136/pdfft?md5=2f4ba2884c69506c71b4bafbd63f8fdf&pid=1-s2.0-S0890850824000136-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and Cellular Probes","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0890850824000136","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

As one of the earliest discovered lncRNA molecules, lncRNA H19 is usually expressed in large quantities during embryonic development and is involved in cell differentiation and tissue formation. In recent years, the role of lncRNA H19 in tumors has been gradually recognized. Increasing evidence suggests that its aberrant expression is closely related to cancer development. LncRNA H19 as an oncogene not only promotes the growth, proliferation, invasion and metastasis of many tumors, but also develops resistance to treatment, affecting patients' prognosis and survival. Therefore, in this review, we summarise the extensive research on the involvement of lncRNA H19 in tumor progression and discuss how lncRNA H19, as a key target gene, affects tumor sensitivity to radiotherapy, chemotherapy and immunotherapy by participating in multiple cellular processes and regulating multiple signaling pathways, which provides a promising prospect for further research into the treatment of cancer.

查看原文本刊更多论文

LncRNA H19 在肿瘤进展和治疗中的作用

作为最早发现的lncRNA分子之一，lncRNA H19通常在胚胎发育过程中大量表达，并参与细胞分化和组织形成。近年来，人们逐渐认识到 lncRNA H19 在肿瘤中的作用。越来越多的证据表明，它的异常表达与癌症的发生发展密切相关。LncRNA H19作为一种癌基因，不仅会促进多种肿瘤的生长、增殖、侵袭和转移，还会产生耐药性，影响患者的预后和生存。因此，在这篇综述中，我们总结了lncRNA H19参与肿瘤进展的大量研究，探讨了lncRNA H19作为一个关键靶基因，如何通过参与多种细胞过程和调控多种信号通路，影响肿瘤对放化疗和免疫治疗的敏感性，为进一步研究癌症的治疗提供了广阔的前景。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular and Cellular Probes 生物-生化研究方法

CiteScore

6.80

自引率

0.00%

发文量

审稿时长

16 days

期刊介绍： MCP - Advancing biology throughâ€“omics and bioinformatic technologies wants to capture outcomes from the current revolution in molecular technologies and sciences. The journal has broadened its scope and embraces any high quality research papers, reviews and opinions in areas including, but not limited to, molecular biology, cell biology, biochemistry, immunology, physiology, epidemiology, ecology, virology, microbiology, parasitology, genetics, evolutionary biology, genomics (including metagenomics), bioinformatics, proteomics, metabolomics, glycomics, and lipidomics. Submissions with a technology-driven focus on understanding normal biological or disease processes as well as conceptual advances and paradigm shifts are particularly encouraged. The Editors welcome fundamental or applied research areas; pre-submission enquiries about advanced draft manuscripts are welcomed. Top quality research and manuscripts will be fast-tracked.